Alnylam’s zilebesiran Phase 2 safety data backs ongoing Phase 3 ZENITH hypertension trial

Reuters03-31

Alnylam’s zilebesiran Phase 2 safety data backs ongoing Phase 3 <a href="https://laohu8.com/S/ZENB.UK">ZENITH</a> hypertension trial

Alnylam highlighted new clinical trial analyses already presented at ACC.26 supporting Amvuttra (vutrisiran) as a first-line option in ATTR cardiomyopathy.
HELIOS-B follow-up showed patients on vutrisiran reported better day-to-day functioning and quality of life versus placebo.
Post hoc findings indicated vutrisiran lowered risk of progression to more advanced disease, with improved survival and cardiovascular outcomes among patients who worsened on study.
Alnylam also disclosed pooled Phase 2 safety results already presented for investigational hypertension drug zilebesiran, supporting continued Phase 3 development in ZENITH, initiated in September 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alnylam Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260330643261) on March 30, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2623340625?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-31 01:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2623340625","market":"fut","top_or_hot":-1,"title":"Alnylam’s zilebesiran Phase 2 safety data backs ongoing Phase 3 ZENITH hypertension trial","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Alnylam’s zilebesiran Phase 2 safety data backs ongoing Phase 3 <a href=\"https://laohu8.com/S/ZENB.UK\">ZENITH</a> hypertension trial\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Alnylam highlighted new clinical trial analyses already presented at ACC.26 supporting Amvuttra (vutrisiran) as a first-line option in ATTR cardiomyopathy.\n        </li>\n<li>\n          HELIOS-B follow-up showed patients on vutrisiran reported better day-to-day functioning and quality of life versus placebo.\n        </li>\n<li>\n          Post hoc findings indicated vutrisiran lowered risk of progression to more advanced disease, with improved survival and cardiovascular outcomes among patients who worsened on study.\n        </li>\n<li>\n          Alnylam also disclosed pooled Phase 2 safety results already presented for investigational hypertension drug zilebesiran, supporting continued Phase 3 development in ZENITH, initiated in September 2025.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alnylam Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260330643261) on March 30, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Alnylam’s zilebesiran Phase 2 safety data backs ongoing Phase 3 ZENITH hypertension trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAlnylam’s zilebesiran Phase 2 safety data backs ongoing Phase 3 ZENITH hypertension trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-31 01:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Alnylam’s zilebesiran Phase 2 safety data backs ongoing Phase 3 <a href=\"https://laohu8.com/S/ZENB.UK\">ZENITH</a> hypertension trial\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Alnylam highlighted new clinical trial analyses already presented at ACC.26 supporting Amvuttra (vutrisiran) as a first-line option in ATTR cardiomyopathy.\n        </li>\n<li>\n          HELIOS-B follow-up showed patients on vutrisiran reported better day-to-day functioning and quality of life versus placebo.\n        </li>\n<li>\n          Post hoc findings indicated vutrisiran lowered risk of progression to more advanced disease, with improved survival and cardiovascular outcomes among patients who worsened on study.\n        </li>\n<li>\n          Alnylam also disclosed pooled Phase 2 safety results already presented for investigational hypertension drug zilebesiran, supporting continued Phase 3 development in ZENITH, initiated in September 2025.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alnylam Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260330643261) on March 30, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nNDLbY1T5M:1","article_id":"2623340625","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2623340625","pubTimestamp":1774890022,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Alnylam highlighted new clinical trial analyses already presented at ACC.26 supporting Amvuttra  as a first-line option in ATTR cardiomyopathy.HELIOS-B follow-up showed patients on vutrisiran reported better day-to-day functioning and quality of life versus placebo.Post hoc findings indicated vutrisiran lowered risk of progression to more advanced disease, with improved survival and cardiovascular outcomes among patients who worsened on study.Alnylam also disclosed pooled Phase 2 safety results already presented for investigational hypertension drug zilebesiran, supporting continued Phase 3 development in ZENITH, initiated in September 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alnylam Pharmaceuticals Inc. published the origi","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","BK4548":"巴美列捷福持仓","BK4139":"生物科技","ALNY":"阿尔尼拉姆制药公司","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU0882574055.USD":"富达全球健康医疗A ACC","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","BK4588":"碎股"},"translate_title":"Alnylam的zilebesiran 2期安全性数据支持正在进行的3期ZENITH高血压试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ALNY":0.9},"content_text":"Alnylam’s zilebesiran Phase 2 safety data backs ongoing Phase 3 ZENITH hypertension trial\n    \n\n\n          Alnylam highlighted new clinical trial analyses already presented at ACC.26 supporting Amvuttra (vutrisiran) as a first-line option in ATTR cardiomyopathy.\n        \n\n          HELIOS-B follow-up showed patients on vutrisiran reported better day-to-day functioning and quality of life versus placebo.\n        \n\n          Post hoc findings indicated vutrisiran lowered risk of progression to more advanced disease, with improved survival and cardiovascular outcomes among patients who worsened on study.\n        \n\n          Alnylam also disclosed pooled Phase 2 safety results already presented for investigational hypertension drug zilebesiran, supporting continued Phase 3 development in ZENITH, initiated in September 2025.\n        \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alnylam Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260330643261) on March 30, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2623340625","isCrawlerRequest":true}